Axsome Therapeutics, Inc. — Form 8-K
Filed August 10, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Q2 2026 net product revenue reached $218.4M (46% YoY growth), driven by AUVELITY sales of $180.3M (51% YoY growth). Company launched AUVELITY for Alzheimer's disease agitation in June 2026, expanded sales force to ~630 reps, and achieved 126% increase in new patient starts among 65+ patients in first 8 weeks post-launch. NDA for AXS-12 (narcolepsy cataplexy) accepted with May 1, 2027 PDUFA date; FOCUS-2 and FOCUS-3 Phase 3 trials initiated for solriamfetol in pediatric ADHD.
Why this rating
Strong commercial execution with meaningful new indication launch and robust pipeline progress; revenue growth meaningful relative to $4.4B market cap; near-term catalysts (AXS-12 decision, Phase 3 data) significant but execution risk remains.
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.